newsfilter
← Latest News
GlobeNewswire·

Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences

  • Scribe Therapeutics Inc. (NASDAQ: SCTX) will have management attend the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA on Nov. 10, 2026, where CEO Benjamin Oakes, Ph.D. will participate in a fireside chat.
  • The company will attend the Stifel Healthcare Conference in New York, NY on Nov. 11, 2026, where CEO Benjamin Oakes, Ph.D. will deliver a presentation.
  • Management will host one-on-one investor meetings in person during London Life Sciences Week from Nov. 15-20, 2026.
  • Scribe Therapeutics is a clinical-stage biotechnology company engineering in vivo CRISPR technologies for cardiometabolic diseases, including ASCVD drivers like elevated LDL-C, lipoprotein(a), & triglycerides.
  • The company's lead candidate, STX-1150, is a liver-targeted therapy designed to epigenetically silence the PCSK9 gene & reduce LDL-C levels without inducing permanent DNA changes.
  • Scribe has formed strategic collaborations with Sanofi & Eli Lilly to accelerate its CRISPR technologies.
  • The company was co-founded by Nobel Prize winner Jennifer Doudna & is backed by leading life sciences investors.